Kyle Rasbach

T. Rowe Price Associates, Inc. (Price Associates) is a registered investment advisor and mutual fund manager headquartered in Baltimore, Maryland. The firm was founded by Thomas Rowe Price, Jr. in 1937. They are a subsidiary of the T. Rowe Price Group, Inc. (NASDAQ: TROW), which was formed in 2000 as the publicly traded parent holding company of Price Associates and their affiliated entities. Price Associates offers a variety of mutual funds, sub-advisory services and separate account management for individual and institutional investors, retirement plans and financial intermediaries.

Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy.

Eventide Asset Management LLC (Eventide) is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. The firm was founded in 2008 by Finni Kuruvilla, Jason Myhre, Roben John, David Barksdale and Anil Thomas. Eventide provides portfolio management for registered mutual funds and offers non-discretionary Model Allocations and Models to financial intermediaries such as wrap fee program sponsors.

Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

Balance Therapeutics, Inc. develops therapeutics to address conditions of intellectual disability. Its pharmacological approach, based on technology licensed from Stanford University, hypothesizes that restoring the proper balance between inhibition and excitation at the neuronal synapse by antagonizing excessive inhibitory circuits could result in the appropriate plasticity for memory and learning to occur in many conditions of intellectual disability. The company was founded by Lyndon Lien, Craig Garner and Daniel Wetmore in 2009 and is headquartered in San Bruno, CA.

Goldfinch Bio, Inc. operates as a biotechnology company. It focuses on discovering and developing precision therapies for patients with kidney disease. The firm develops and manufactures medicines. The company was founded by Joseph Vincent Bonventre, Anna Greka, Fridhelm Hildebrandt, Daniel MacArthur, Stefan Somlo and Peter Mundel in December 2016 and is headquartered in Cambridge, MA.